Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Purpose
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions
- Intracranial Meningioma
- Recurrent Meningioma
- NF2 Gene Mutation
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
- Documentation of disease:
- Histologic documentation: histologically proven intracranial meningioma as
documented by central pathology review
- Molecular documentation: Presence of SMO, PTCH1, NF2, CDKN2A, AKT1, PIK3CA,
PTEN mutations, CDKN2A copy number loss, CDK4, CDK6, CCND1, CCND2, CCND3, or
CCNE1 copy number gain in tumor sample as documented specifically by the
central laboratory, regardless of whether prior genotype testing outside of the
central laboratory was performed
- Progressive OR residual disease, as defined by the following:
- Residual measurable disease: residual measurable disease immediately after
surgery without requirement for progression; for grade I disease,
progression pre-operatively needs to be documented, with an increase in
size of the measurable primary lesion on imaging by 25% or more
(bidirectional area); the change must occur between scans separated by no
more than 25 months; for patients with SMO/PTCH1 mutations enrolling to
receive vismodegib, the change can occur between scans separated by up to
25 months; residual measurable disease will be defined by bidimensionally
measurable lesions with clearly defined margins by MRI scans, with a
minimum diameter of 10 mm in both dimensions
- Progressive measurable disease: progression defined as an increase in size
of the measurable primary lesion on imaging by 25% or more (bidirectional
area); the change must occur between scans separated by no more than 25
months
- Post radiation patients: patients with measurable and progressive
meningioma who have received radiation are potentially eligible, but need
to show evidence of progressive disease after completion of radiation; if
the progressive meningioma lesion has been radiated, at least 24 weeks
must have elapsed from completion of radiation to registration; if the
progressive lesion is outside of the radiation field, then an interval of
at least 2 weeks must have elapsed from completion of radiation to
registration
- Measurable disease: measurable disease is defined by a bidimensionally measurable
main lesion on MRI or computed tomography (CT) images (MRI preferred) with clearly
defined margins and a minimum diameter of 10 mm in both dimensions; multifocal
disease is allowed
- Prior treatment
- Prior medical therapy is allowed but not required
- No limit on number of prior therapies
- No chemotherapy, or other investigational agents within 28 days prior to
registration
- No other concurrent investigational agents or other meningioma-directed therapy
(chemotherapy, radiation) while on study; additionally, no cases of nitrosourea
or mitomycin C within 6 weeks prior to registration
- For patients treated with external beam radiation, interstitial brachytherapy
or radiosurgery, an interval > 4 weeks must have elapsed from completion of
radiation therapy to registration; if the progressive lesion is outside of the
radiation field, then an interval of at least 2 weeks must have elapsed from
completion of radiation to registration
- Steroid dosing stable for at least 4 days
- Recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or
less toxicity from other agents with exception of alopecia and fatigue
- No craniotomy 28 days prior to and after registration
- Not pregnant and not nursing:
* A female of childbearing potential is a sexually mature female who: 1) has not
undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
postmenopausal for at least 12 consecutive months (i.e., has had menses at any time
in the preceding 12 consecutive months)
- For patients with NF2/CDKN2A/AKT1/PIK3CA/PTEN mutation, CKDN2A copy number loss, or
CDK4/CDK6/CCND1/CCND2/CCND3/CCNE1 copy number gain: Age >= 18 years
- For patients with SMO/PTCH1 mutation: Age >= 30 years
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Patient history:
- Patients with history of neurofibromatosis (NF) may have other stable central
nervous system (CNS) tumors (schwannoma, acoustic neuroma or ependymoma) if
lesions have been stable for 6 months
- No metastatic meningiomas (as defined by extracranial meningiomas outside of
CNS) allowed; spinal meningiomas are allowed
- No history of allergic reactions attributed to compounds of similar or biologic
composition to assigned study drug
- No known active hepatitis B or C
- No current Child Pugh class B or C liver disease
- No uncontrolled gastric ulcer disease (grade 3 gastric ulcer disease within 28
days of registration)
- No uncontrolled hypertension defined as blood pressure (BP) > 140/90
- No abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal
abscess within 28 days prior to registration
- No major surgery within 28 days prior to registration for any patients with
AKT1/PIK3CA/PTEN mutations receiving capivasertib
- For patients going on to receive capivasertib (i.e. enrolled after Update #08)
- Patients should not have any of the following cardiac criteria:
- Any clinically important abnormalities in rhythm, conduction, or
morphology of resting electrocardiogram (EKG) (e.g., complete left
bundle branch block, third degree heart block)
- Any factors that increase the risk of corrected QT (QTc) prolongation
or risk of arrhythmic events such as heart failure, hypokalemia,
potential for Torsade de Pointes, congenital long QT syndrome, family
history of long QT syndrome, or unexplained sudden death under 40
years of age, or any concomitant medication known to prolong the QT
interval
- Experience any of the following procedures or conditions in the
preceding 6 months: coronary artery bypass graft, angioplasty,
vascular stent, myocardial infarction, angina pectoris, congestive
heart failure New York Heart Association (NYHA) class >= II
- Uncontrolled hypertension (systolic blood pressure [SBP] < 90 mmHg
and/or diastolic blood pressure [DBP] < 50 mmHg)
- Cardiac ejection fraction outside institutional range of normal or <
50% (whichever is higher) as measured by echocardiogram (or
multigated acquisition [MUGA] scan if an echocardiogram can't be
performed or is inconclusive); left ventricular ejection fraction
(LVEF) below lower limit of normal for site
- Patients should not have any of the following criteria:
- With the exception of alopecia, any unresolved toxicities from prior
therapy greater than Common Terminology Criteria for Adverse Events
(CTCAE) grade 1 at the time of registration
- Hemoglobin < 9 g/dL (< 5.59 mmol/L); note: any blood transfusion must
be >= 14 days prior to the determination of a hemoglobin >= 9 g/dL
(>= 5.59 mmol/L)
- Proteinuria 3+ on dipstick analysis or > 500 mg/24 hours
- Refractory nausea and vomiting, chronic gastrointestinal diseases,
inability to swallow the formulated product or previous significant
bowel resection that would preclude adequate absorption of
capivasertib
- History of hypersensitivity to active or inactive excipients of
capivasertib or drugs with a similar chemical structure or class to
capivasertib
- Current disease or condition known to interfere with absorption,
distribution, metabolism, or excretion of drugs
- Past medical history of interstitial lung disease, drug-induced
interstitial lung disease, radiation pneumonitis which required
steroid treatment, or any evidence of clinically active interstitial
lung disease
- Previous allogeneic bone marrow transplant
- Known immunodeficiency syndrome
- Concomitant medications (only regarding
NF2/CDKN2A/CDK4/CDK6/CCND1/CCND2/CCND3/CCNE1/AKT1/PIK3CA/PTEN genetic alterations):
- Chronic concomitant treatment with strong inhibitors of cytochrome P450, family
3, subfamily A, polypeptide 4 (CYP3A4) inhibitors must discontinue the drug for
14 days prior to registration on the study for patients with NF2 mutation
enrolled to GSK2256098, as well as for patients with AKT1/PIK3CA/PTEN mutations
enrolled to capivasertib
- For NF2 patients going on to receive GSK2256098 and for patients with
AKT1/PIK3CA/PTEN mutations enrolled to capivasertib: concomitant treatment with
strong CYP3A4 inducers or CYP2D6 substrates is not allowed; patients must
discontinue the drug 14 days prior to registration
- For NF2 patients going on to receive abemaciclib: avoid concomitant use of
CYP3A inducers and strong CYP3A inhibitors; use caution with coadministered
moderate or weak CYP3A inhibitors
- Diabetic status:
- For patients with NF2 or SMO/PTCH1 mutations: No uncontrolled diabetes defined
as a known diabetic with HBA1C > 7.5 OR fasting glucose > 140 mg/dL.
- For patients with AKT1/PIK3CA/PTEN mutations:
- Glycosylated hemoglobin (HbA1C) < 8.0% (63.9 mmol/mol)
- No type 1 diabetes mellitus
- No requirement for insulin for routine diabetic management and control
- No requirement for more than two oral hypoglycemic medications for routine
diabetic management and control
- Patients with a pre-existing diagnosis of type 2 diabetes mellitus must
have fasting glucose < 9.3 mmol/L (167mg/dL); fasting is defined as no
caloric intake for at least 8 hours
- Patients without a pre-existing diagnosis of type 2 diabetes mellitus must have
fasting glucose =< 7.0 mmol/L (126 mg/dL); fasting is defined as no caloric
intake for at least 8 hours
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Creatinine OR =< 1.5 mg/dl x upper limit of normal (ULN) OR calculated (calc.)
creatinine clearance > 50 mL/min
- Urine protein:creatinine ratio (UPC) =< 45 mg/mmol
- Total bilirubin =< 1.5 x upper limit of normal (ULN); except in case of Gilbert's
disease
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
- Sodium, potassium, total calcium (corrected for serum albumin) & phosphorus within
normal limits per institutional guidelines
- QTcF < 450 msec (QT calculated using Fridericia formula)
- Mean resting heart rate (determined from EKG) 50-100 beats per minute (BMP) (must be
obtained from 12-lead EKG defined by a triplicate EKG for patients assigned to the
capivasertib arm; patients assigned to all other arms will require a single EKG
- No uncontrolled medical comorbidities per investigator discretion (e.g. interstitial
lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major
surgical resection involving the stomach or small bowel, or pre-existing Crohn's
disease or ulcerative colitis or a preexisting chronic condition resulting in
baseline Grade 2 or higher diarrhea)
- ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: Hemoglobin >= 8
g/dL
* Patients may receive erythrocyte transfusions to achieve this hemoglobin level at
the discretion of the investigator; initial treatment must not begin earlier than
the day after the erythrocyte transfusion
- ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: Prior Treatment
- Patients who received chemotherapy must have recovered (Common Terminology
Criteria for Adverse Events [CTCAE] grade =< 1) from the acute effects of
chemotherapy except for residual alopecia or grade 2 peripheral neuropathy
prior to registration; a washout period of at least 28 days is required between
last chemotherapy dose and registration (provided the patient did not receive
radiotherapy)
- Patients who received adjuvant radiotherapy must have completed and fully
recovered from the acute effects of radiotherapy; a washout period of at least
28 days is required between end of radiotherapy and registration
- ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: No active
bacterial infection (requiring intravenous [IV] antibiotics at time of initiating
study treatment), fungal infection, or detectable viral infection (such as known
human immunodeficiency virus positivity or with known active hepatitis B or C [for
example, hepatitis B surface antigen positive]); screening is not required for
enrollment in the absence of symptoms
- ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: No personal
history of any of the following conditions: syncope of cardiovascular etiology,
ventricular arrhythmia of pathological origin (including, but not limited to,
ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Non-Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Arm A (vismodegib) |
Patients receive vismodegib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL FEBRUARY 2018) |
|
|
Experimental Arm B (FAK inhibitor GSK2256098) |
Patients receive FAK inhibitor GSK2256098 PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL JULY 2017) |
|
|
Experimental Arm C (capivasertib) |
Patients receive capivasertib PO BID on days 1-4. Treatment repeats every 7 days for up to 1 cycle (28 days) in the absence of disease progression or unacceptable toxicity. |
|
|
Experimental Arm D (abemaciclib) |
Patients receive abemaciclib PO Q12H. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
|
Recruiting Locations
Anchorage, Alaska 98508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Kingman, Arizona 86401
Phoenix, Arizona 85004
Fort Smith, Arkansas 72903
Site Public Contact
800-378-9373
Little Rock, Arkansas 72205
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Burbank, California 91505
Carmichael, California 95608
Carmichael, California 95608
Elk Grove, California 95758
La Jolla, California 92093
Los Angeles, California 90027
Los Angeles, California 90048
Site Public Contact
310-423-8965
Merced, California 95340
Rocklin, California 95765
Sacramento, California 95816
San Luis Obispo, California 93401
Santa Maria, California 93444
Stockton, California 95204
Site Public Contact
209-461-5257
Torrance, California 90505
Torrance, California 90509
Site Public Contact
310-517-4665
Woodland, California 95695
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80923
Durango, Colorado 81301
Durango, Colorado 81301
Lakewood, Colorado 80228
Longmont, Colorado 80501
Pueblo, Colorado 81004
Westminster, Colorado 80023
Hartford, Connecticut 06105
New Haven, Connecticut 06520
Trumbull, Connecticut 06611
Boca Raton, Florida 33486
Site Public Contact
561-955-4800
Deerfield Beach, Florida 33442
Site Public Contact
305-243-2647
Fort Lauderdale, Florida 33308
Hollywood, Florida 33021
Miami, Florida 33136
Site Public Contact
305-243-2647
Pembroke Pines, Florida 33028
Site Public Contact
954-265-4325
Plantation, Florida 33324
Site Public Contact
305-243-2647
Tampa, Florida 33606
Atlanta, Georgia 30303
Site Public Contact
404-778-1868
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Boise, Idaho 83706
Boise, Idaho 83712
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Fruitland, Idaho 83619
Meridian, Idaho 83642
Meridian, Idaho 83642
Nampa, Idaho 83687
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Twin Falls, Idaho 83301
Alton, Illinois 62002
Site Public Contact
618-463-5623
Barrington, Illinois 60010
Site Public Contact
847-842-4847
Bloomington, Illinois 61704
Canton, Illinois 61520
Carbondale, Illinois 62902
Carterville, Illinois 62918
Carthage, Illinois 62321
Centralia, Illinois 62801
Chicago, Illinois 60612
Chicago, Illinois 60657
Site Public Contact
773-296-5360
Crystal Lake, Illinois 60014
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Downers Grove, Illinois 60515
Effingham, Illinois 62401
Effingham, Illinois 62401
Elgin, Illinois 60123
Site Public Contact
847-429-2907
Eureka, Illinois 61530
Galesburg, Illinois 61401
Hazel Crest, Illinois 60429
Site Public Contact
708-799-9995
Kewanee, Illinois 61443
Libertyville, Illinois 60048
Libertyville, Illinois 60048
Macomb, Illinois 61455
Mattoon, Illinois 61938
Mount Vernon, Illinois 62864
O'Fallon, Illinois 62269
O'Fallon, Illinois 62269
Oak Lawn, Illinois 60453-2699
Site Public Contact
800-323-8622
Oak Lawn, Illinois 60453
Oak Park, Illinois 60304
Ottawa, Illinois 61350
Palos Heights, Illinois 60463
Park Ridge, Illinois 60068
Site Public Contact
847-384-3621
Pekin, Illinois 61554
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61615
Peoria, Illinois 61636
Peoria, Illinois 61637
Peru, Illinois 61354
Peru, Illinois 61354
Site Public Contact
815-664-4141
Princeton, Illinois 61356
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Urbana, Illinois 61801
Urbana, Illinois 61801
Washington, Illinois 61571
Yorkville, Illinois 60560
Ankeny, Iowa 50023
Site Public Contact
515-241-3305
Clive, Iowa 50325
Site Public Contact
515-241-3305
Clive, Iowa 50325
Site Public Contact
515-241-3305
Creston, Iowa 50801
Site Public Contact
515-241-3305
Des Moines, Iowa 50309
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Des Moines, Iowa 50314
Site Public Contact
515-241-3305
Iowa City, Iowa 52242
Site Public Contact
800-237-1225
Waukee, Iowa 50263
Site Public Contact
515-241-3305
West Des Moines, Iowa 50266
Site Public Contact
515-241-3305
Great Bend, Kansas 67530
Pittsburg, Kansas 66762
Site Public Contact
888-446-3729
Bardstown, Kentucky 40004
Corbin, Kentucky 40701
Lexington, Kentucky 40504
Lexington, Kentucky 40504
Lexington, Kentucky 40509
London, Kentucky 40741
Louisville, Kentucky 40241
Mount Sterling, Kentucky 40353
Baltimore, Maryland 21287
Boston, Massachusetts 02111
Boston, Massachusetts 02114
Site Public Contact
877-726-5130
Alma, Michigan 48801
Alpena, Michigan 49707
Ann Arbor, Michigan 48106
Battle Creek, Michigan 49017
Brighton, Michigan 48114
Brighton, Michigan 48114
Brownstown, Michigan 48183
Canton, Michigan 48188
Canton, Michigan 48188
Chelsea, Michigan 48118
Chelsea, Michigan 48118
Clarkston, Michigan 48346
Clarkston, Michigan 48346
Clinton Township, Michigan 48038
Dearborn, Michigan 48126
Detroit, Michigan 48202
Detroit, Michigan 48236
East China Township, Michigan 48054
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Flint, Michigan 48503
Gladwin, Michigan 48624
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Grosse Pointe Woods, Michigan 48236
Grosse Pointe Woods, Michigan 48236
Grosse Pointe Woods, Michigan 48236
Jackson, Michigan 49201
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49009
Site Public Contact
574-647-7370
Kalamazoo, Michigan 49048
Site Public Contact
574-647-7370
Lansing, Michigan 48912
Livonia, Michigan 48154
Macomb, Michigan 48044
Macomb, Michigan 48044
Midland, Michigan 48670
Mount Pleasant, Michigan 48858
Muskegon, Michigan 49444
Niles, Michigan 49120
Site Public Contact
616-391-1230
Norton Shores, Michigan 49444
Novi, Michigan 48377
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Pontiac, Michigan 48341
Reed City, Michigan 49677
Saginaw, Michigan 48601
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Tawas City, Michigan 48764
Traverse City, Michigan 49684
Warren, Michigan 48093
Warren, Michigan 48093
Warren, Michigan 48093
West Bloomfield, Michigan 48322
Wyoming, Michigan 49519
Ypsilanti, Michigan 48106
Ypsilanti, Michigan 48197
Aitkin, Minnesota 56431
Baxter, Minnesota 56425
Site Public Contact
218-828-2880
Brainerd, Minnesota 56401
Burnsville, Minnesota 55337
Cambridge, Minnesota 55008
Chaska, Minnesota 55318
Coon Rapids, Minnesota 55433
Coon Rapids, Minnesota 55433
Crosslake, Minnesota 56442
Site Public Contact
218-692-1010
Deer River, Minnesota 56636
Detroit Lakes, Minnesota 56501
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Duluth, Minnesota 55805
Edina, Minnesota 55435
Edina, Minnesota 55435
Ely, Minnesota 55731
Site Public Contact
218-365-7900
Fosston, Minnesota 56542
Hibbing, Minnesota 55746
Site Public Contact
218-786-3308
International Falls, Minnesota 56649
Site Public Contact
218-283-9431
Maple Grove, Minnesota 55369
Maple Grove, Minnesota 55369
Maplewood, Minnesota 55109
Maplewood, Minnesota 55109
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55415
Minneapolis, Minnesota 55454
Monticello, Minnesota 55362
Moose Lake, Minnesota 55767
Site Public Contact
218-485-4481
New Ulm, Minnesota 56073
Park Rapids, Minnesota 56470
Pequot Lakes, Minnesota 56472
Site Public Contact
218-568-4416
Pine River, Minnesota 56474
Site Public Contact
218-587-4416
Princeton, Minnesota 55371
Robbinsdale, Minnesota 55422
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Sandstone, Minnesota 55072
Shakopee, Minnesota 55379
Staples, Minnesota 56479
Site Public Contact
218-894-7870
Stillwater, Minnesota 55082
Virginia, Minnesota 55792
Waconia, Minnesota 55387
Willmar, Minnesota 56201
Woodbury, Minnesota 55125
Wyoming, Minnesota 55092
Jackson, Mississippi 39216
Site Public Contact
601-815-6700
Ballwin, Missouri 63011
Site Public Contact
888-446-3729
Branson, Missouri 65616
Site Public Contact
417-269-4520
Cape Girardeau, Missouri 63703
Site Public Contact
888-446-3729
Cape Girardeau, Missouri 63703
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Joplin, Missouri 64804
Joplin, Missouri 64804
Osage Beach, Missouri 65065
Rolla, Missouri 65401
Site Public Contact
573-458-6379
Rolla, Missouri 65401
Saint Joseph, Missouri 64506
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Springfield, Missouri 65807
Site Public Contact
417-269-4520
St Louis, Missouri 63109
Site Public Contact
888-446-3729
St Louis, Missouri 63110
St Louis, Missouri 63128
St Louis, Missouri 63131
Site Public Contact
314-996-5569
St Louis, Missouri 63141
Site Public Contact
314-251-7066
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Washington, Missouri 63090
Site Public Contact
636-390-1600
Billings, Montana 59101
Bozeman, Montana 59715
Great Falls, Montana 59405
Havre, Montana 59501
Helena, Montana 59601
Kalispell, Montana 59901
Missoula, Montana 59802
Missoula, Montana 59804
Grand Island, Nebraska 68803
Kearney, Nebraska 68847
Omaha, Nebraska 68122
Omaha, Nebraska 68124
Omaha, Nebraska 68130
Omaha, Nebraska 68131
Carson City, Nevada 89703
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89074
Henderson, Nevada 89074
Henderson, Nevada 89074
Henderson, Nevada 89074
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
Las Vegas, Nevada 89103
Las Vegas, Nevada 89106
Las Vegas, Nevada 89106
Las Vegas, Nevada 89109
Las Vegas, Nevada 89113
Las Vegas, Nevada 89113
Las Vegas, Nevada 89119
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89135
Las Vegas, Nevada 89144
Las Vegas, Nevada 89144
Las Vegas, Nevada 89144
Las Vegas, Nevada 89148
Las Vegas, Nevada 89148
Las Vegas, Nevada 89169
Las Vegas, Nevada 89169
Pahrump, Nevada 89048
Reno, Nevada 89502
Reno, Nevada 89503
Reno, Nevada 89509
Lebanon, New Hampshire 03756
Neptune City, New Jersey 07753
Site Public Contact
732-776-4240
Summit, New Jersey 07902
Site Public Contact
908-522-2043
Albuquerque, New Mexico 87106
Lake Success, New York 11042
Site Public Contact
516-734-8896
New York, New York 10016
New York, New York 10032
New York, New York 10065
Site Public Contact
212-746-1848
Winston-Salem, North Carolina 27157
Site Public Contact
336-713-6771
Fargo, North Dakota 58103
Jamestown, North Dakota 58401
Belpre, Ohio 45714
Chillicothe, Ohio 45601
Cincinnati, Ohio 45219
Cincinnati, Ohio 45220
Cincinnati, Ohio 45242
Cincinnati, Ohio 45247
Cincinnati, Ohio 45255
Cleveland, Ohio 44106
Cleveland, Ohio 44195
Columbus, Ohio 43213
Columbus, Ohio 43219
Columbus, Ohio 43222
Grove City, Ohio 43123
Grove City, Ohio 43123
Lancaster, Ohio 43130
Lima, Ohio 45801
Marietta, Ohio 45750
Marysville, Ohio 43040
Mount Vernon, Ohio 43050
New Albany, Ohio 43054
Newark, Ohio 43055
Newark, Ohio 43055
Perrysburg, Ohio 43551
Portsmouth, Ohio 45662
Springfield, Ohio 45504
Springfield, Ohio 45504
Toledo, Ohio 43608
Toledo, Ohio 43623
Toledo, Ohio 43623
West Chester, Ohio 45069
Westerville, Ohio 43081
Wilmington, Ohio 45177
Zanesville, Ohio 43701
Oklahoma City, Oklahoma 73104
Oklahoma City, Oklahoma 73120
Site Public Contact
405-752-3402
Baker City, Oregon 97814
Bend, Oregon 97701
Clackamas, Oregon 97015
Coos Bay, Oregon 97420
Hood River, Oregon 97031
Newberg, Oregon 97132
Ontario, Oregon 97914
Oregon City, Oregon 97045
Portland, Oregon 97213
Portland, Oregon 97225
Redmond, Oregon 97756
Site Public Contact
541-706-2909
Allentown, Pennsylvania 18103
Bethlehem, Pennsylvania 18017
East Stroudsburg, Pennsylvania 18301
Hazleton, Pennsylvania 18201
Hershey, Pennsylvania 17033-0850
Philadelphia, Pennsylvania 19104
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Boiling Springs, South Carolina 29316
Easley, South Carolina 29640
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Greenville, South Carolina 29605
Greenville, South Carolina 29615
Greer, South Carolina 29650
Seneca, South Carolina 29672
Houston, Texas 77030
Houston, Texas 77030
Site Public Contact
713-792-3245
Humble, Texas 77338
The Woodlands, Texas 77380
Berlin Corners, Vermont 05602
Site Public Contact
802-225-5400
Burlington, Vermont 05401
Burlington, Vermont 05405
Saint Johnsbury, Vermont 05819
Charlottesville, Virginia 22908
Fairfax, Virginia 22031
Richmond, Virginia 23298
Aberdeen, Washington 98520
Bellingham, Washington 98225
Centralia, Washington 98531
Edmonds, Washington 98026
Everett, Washington 98201
Issaquah, Washington 98029
Kennewick, Washington 99336
Lacey, Washington 98503
Longview, Washington 98632
Mount Vernon, Washington 98274
Renton, Washington 98055
Seattle, Washington 98107
Seattle, Washington 98122-5711
Seattle, Washington 98122
Sedro-Woolley, Washington 98284
Silverdale, Washington 98383
Spokane, Washington 99202
Spokane, Washington 99216
Spokane, Washington 99218
Vancouver, Washington 98664
Walla Walla, Washington 99362
Yakima, Washington 98902
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Burlington, Wisconsin 53105
Chippewa Falls, Wisconsin 54729
Cudahy, Wisconsin 53110
Eau Claire, Wisconsin 54701
Fond du Lac, Wisconsin 54937
Germantown, Wisconsin 53022
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54311
Hayward, Wisconsin 54843
Site Public Contact
218-568-4416
Kenosha, Wisconsin 53142
Marinette, Wisconsin 54143
Marshfield, Wisconsin 54449
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53233
Minocqua, Wisconsin 54548
New Richmond, Wisconsin 54017
Oshkosh, Wisconsin 54904
Racine, Wisconsin 53406
Rice Lake, Wisconsin 54868
Sheboygan, Wisconsin 53081
Stevens Point, Wisconsin 54482
Summit, Wisconsin 53066
Two Rivers, Wisconsin 54241
Wausau, Wisconsin 54401
Wauwatosa, Wisconsin 53226
West Allis, Wisconsin 53227
Weston, Wisconsin 54476
Cheyenne, Wyoming 82001
Cody, Wyoming 82414
More Details
- Status
- Recruiting
- Sponsor
- Alliance for Clinical Trials in Oncology
Study Contact
Priscilla Brastianos, MD617-643-1939
Detailed Description
PRIMARY OBJECTIVES: I. To determine the activity of a SMO inhibitor in patients with meningiomas harboring SMO and PTCH1 mutations as measured by 6-month progression free survival (PFS) and response rate. II. To determine the activity of a FAK inhibitor in patients with meningiomas harboring NF2 mutations as measured by 6-month PFS and response rate. III. To determine the activity of an AKT inhibitor in patients with meningiomas harboring AKT1/PIK3CA/PTEN mutations as measured by 6-month PFS and response rate. IV. To determine the activity of a CDK inhibitor in patients with meningiomas harboring alterations in the CDK pathway or NF2 alterations as measured by 6-month PFS and response rate. SECONDARY OBJECTIVES: I. To determine overall survival and progression-free survival of SMO, FAK, AKT and CDK inhibitors in patients with meningioma. II. To determine adverse event rates of SMO, FAK, AKT and CDK inhibitors in patients with meningioma. III. To determine the activity of SMO, FAK, AKT and CDK inhibitors as measured by response rate by central radiology review. OUTLINE: Patients are assigned to 1 of 4 treatment arms based on their mutation status. ARM A (SMO/PTCH1 mutation): Patients receive vismodegib orally (PO) once daily (QD). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL FEBRUARY 2018) ARM B (NF2 mutation): Patients receive FAK inhibitor GSK2256098 PO twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL JULY 2017) ARM C (AKT1, PIK3CA, or PTEN mutation): Patients receive capivasertib PO BID on days 1-4. Treatment repeats every 7 days for up to 1 cycle (28 days) in the absence of disease progression or unacceptable toxicity. ARM D (CDK4, CDK6, CDKN2A, CCND1, CCND2, CCND3, CCNE1 alterations): Patients receive abemaciclib PO every 12 hours (Q12H). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 6 months for a maximum of 5 years from registration.